Inovio Pharmaceuticals Inc (INO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.32-7.04%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Inovio aims to reduce operational net cash burn to about $18 million in 2026-Q2. The company recently beat earnings twice, showing some progress. Revenue estimates rise from $2.3 million in 2026-Q3 to $69 million in 2027, signaling potential growth.
Inovio remains loss-making with negative EPS of -$1.14 expected in 2026. Cash burn is still high near $18 million per quarter. The stock has fallen 17% from its high, reflecting elevated risk and weak financial health.
The market prices in a high implied growth of 44% over 3 years but also reflects the company’s ongoing losses and cash burn. Our fair value is $0.38, indicating limited upside versus current risk.
Breaks if: EPS loss worsens or remains below -$1.0 in 2027
Breaks if: operational net cash burn exceeds $18 million in 2026-Q2
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity focused on advancing INO-3107 toward FDA approval. The current thesis state is cautious, as the company is loss-making and faces elevated risks, but has shown recent positive momentum.
The market appears to be pricing in a premium compared to peers, reflecting the optionality of INO-3107's potential success. However, this premium is coupled with a fragile valuation, as the company's financial performance has not yet matched that of its industry cohort.
Management is on track with cost control and capital raises, which supports operations through early 2027. However, the company remains loss-making, and the risk of missing future guidance is present, especially in a high-miss-rate industry.
The long-term thesis hinges on the successful advancement of INO-3107 toward FDA approval and the overall health of the healthcare sector. Key triggers include potential guidance cuts or continued positive earnings from sector leaders, which could influence investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a more favorable outlook. Additionally, progress toward FDA approval for INO-3107 reinforces expectations for a commercial launch. There are no new threats identified that could weaken this positive view.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on reducing operational net cash burn to manage financial sustainability.
Breaks if: revenue fails to grow above $10 million in 2026 or $50 million in 2027
In the next 1 to 3 years, INO's performance will depend on its ability to manage risks and execute on its strategic priorities. Not investment advice.